Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Brian Matthew Wolpin, M.D.

Co-Author

This page shows the publications co-authored by Brian Wolpin and Lawrence Blaszkowsky.
Connection Strength

1.124
  1. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801.
    View in: PubMed
    Score: 0.212
  2. Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist. 2013; 18(4):377-8.
    View in: PubMed
    Score: 0.134
  3. Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. Ann Oncol. 2013 Jul; 24(7):1792-1801.
    View in: PubMed
    Score: 0.133
  4. Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). J Clin Oncol. 2011 May 20; 29(15_suppl):4031.
    View in: PubMed
    Score: 0.117
  5. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009 Jan 10; 27(2):193-8.
    View in: PubMed
    Score: 0.099
  6. Phase II study of RAD001 in previously treated patients with metastatic pancreatic cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):4614.
    View in: PubMed
    Score: 0.095
  7. Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):208-13.
    View in: PubMed
    Score: 0.085
  8. A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33(1):128-37.
    View in: PubMed
    Score: 0.037
  9. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Pract Radiat Oncol. 2014 Mar-Apr; 4(2):e117-e123.
    View in: PubMed
    Score: 0.034
  10. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One. 2012; 7(6):e38231.
    View in: PubMed
    Score: 0.032
  11. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist. 2012; 17(1):14.
    View in: PubMed
    Score: 0.031
  12. Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab. Oncologist. 2012; 17(1):14-e35.
    View in: PubMed
    Score: 0.031
  13. A phase 2 study of oral MKC-1, an inhibitor of importin-ß, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Invest New Drugs. 2012 Aug; 30(4):1614-20.
    View in: PubMed
    Score: 0.030
  14. A single-arm trial of panitumumab in cetuximab refractory KRAS wild-type colorectal cancer. J Clin Oncol. 2011 Feb; 29(4_suppl):428.
    View in: PubMed
    Score: 0.029
  15. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011 Jun; 22(6):1367-1373.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.